A5052573263- Glioma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Trigeminal Neuralgia and Treatments
- Management of metastatic bone disease
- Head and Neck Surgical Oncology
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Vascular Malformations Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Childhood Cancer Survivors' Quality of Life
- Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Sarcoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
University of Maryland, Baltimore
2016-2025
University of Maryland Medical Center
2016-2025
Staten Island University Hospital
2025
Northwell Health
2025
University of Hong Kong
2025
University of Maryland Medical System
2007-2023
University Hospital of Bern
2021
University of Bern
2021
U-M Rogel Cancer Center
2004-2021
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2014-2020
The initial report of NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0424 demonstrated a 3-year overall survival benefit with the addition temozolomide to radiotherapy compared historical control. However, an important end point trial-evaluation association between O6-methylgaunine-DNA-methyltransferase (MGMT) promoter methylation and outcomes-was not previously reported.To examine proportion patients in Oncology/RTOG MGMT its outcomes.Specimens collected were analyzed after trial...
With advances in the understanding of histopathology on outcome, accurate meningioma grading becomes critical and drives treatment selection. The 2000 2007 WHO schema greatly increased proportion grade II meningiomas. Although associations with progression-free survival (PFS) overall (OS) have been independently validated, interobserver concordance has not formally assessed. Once mature, NRG Oncology RTOG-0539 will report PFS OS variably treated low-, intermediate-, high-risk cohorts. We...
Summary Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed‐refractory multiple myeloma ( RRMM ) and malignant glioma. Central nervous system‐multiple CNS ‐ MM rare manifestation of extra‐medullary disease with few therapeutic options, highlighting the unmet clinical need these patients. Marizomib demonstrated encouraging activity has emerging glioma, making it potential intervention. Herein, we present two patients...
Background/Objectives: The Pediatric Proton Consortium Registry (PPCR) was established to expedite proton outcomes research in the pediatric population requiring radiotherapy. Here we introduce PPCR as a resource oncology community and provide an overview of data available for further study collaboration. Design/Methods: A multi-institutional registry integrated clinical, dosimetric, radiographic, patient-reported patients undergoing radiation therapy conceived May 2010. Massachusetts...
Abstract Background Hypofractionated-SRS (HF-SRS) may allow for improved local control and a reduced risk of radiation necrosis compared to single-fraction-SRS (SF-SRS). However, data comparing these two treatment approaches are limited. The purpose this study was compare clinical outcomes between SF-SRS versus HF-SRS across our multi-center academic network. Methods Patients treated with or brain metastasis from 2013 2018 5 oncology centers were retrospectively reviewed. dosing...
The object of this study was to assess outcomes in patients with arteriovenous malformations (AVMs) treated by Gamma Knife stereotactic radiosurgery (SRS); lesions were stratified size, symptomatology, and Spetzler-Martin (S-M) grade.The authors performed a retrospective analysis 102 for an AVM single-dose or staged-dose SRS between 1993 2004. Lesions grouped S-M grade, as hemorrhagic nonhemorrhagic, small (< 3 cm) large (≥ cm). Outcomes included death, morbidity (new neurological deficit,...
The Pediatric Proton/Photon Consortium Registry (PPCR) is a comprehensive data registry composed of pediatric patients treated with radiation. It was established to expedite outcomes-based research. attributes which allow the PPCR be successful collaboration are reviewed.Current eligibility criteria radiotherapy < 22 years at one 15 US participating institutions. Detailed health and treatment collected about disease presentation exposures, annually thereafter, in REDCap (Research Electronic...
Abstract Background Children with brain tumors can experience symptom burden throughout their disease continuum. The aim of the study was to evaluate reported by children and factors that potentially were associated symptoms. Methods Data from 199 aged 7–22 (mean age = 14 years; 52% males; 76% white) analyzed. Symptom assessed using Patient‐Reported Outcomes Measurement Information System (PROMIS) via computerized adaptive testing (CAT)—anxiety, depression, fatigue, mobility, upper extremity...